Concord Drugs Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 538965?
Owner Type	Number of Shares	Ownership Percentage
General Public	1,527,716	15.3%
Individual Insiders	8,472,284	84.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 17 shareholders own 84.72% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
28.6%	Seelam Reddy	2,860,536	₹107.5m	-1.78%	no data
16.3%	M. Reddy	1,628,125	₹61.2m	0%	no data
16.3%	Seelam Manoj Reddy	1,628,000	₹61.2m	0%	no data
9.51%	Seelam Reddy	950,543	₹35.7m	-4.95%	no data
2%	P Prasanna	200,000	₹7.5m	0%	no data
1.69%	Rajendra Agarwal	168,633	₹6.3m	0%	no data
1.3%	Sushil Agarwal	130,400	₹4.9m	0%	no data
1.3%	Manju Agarwal	130,140	₹4.9m	0%	no data
1.21%	S.N. Devi	121,200	₹4.6m	0%	no data
1.05%	K. Reddy	104,600	₹3.9m	0%	no data
1%	Mohan Thodupunuri	100,006	₹3.8m	0%	no data
1%	Ekta Vijaywargi	100,000	₹3.8m	0%	no data
1%	Lokesh Sannuthi	100,000	₹3.8m	0%	no data
1%	Chandra Sannuthi	100,000	₹3.8m	0%	no data
1%	K. Rakesh	100,000	₹3.8m	0%	no data
0.5%	Kommula Reddy	50,100	₹1.9m	0%	no data
0.00001%	Nagavenkata Hareesh Solleti	1	₹37.6	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 11:29
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Concord Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution